Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
27 Febbraio 2024 - 3:00PM
Business Wire
The KnowU incorporates the sensor intended for
FDA submission
Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today announced the
KnowU™, its wearable non-invasive continuous glucose monitor (CGM).
The Company announced its first prototype in June 2023. The KnowU
is the result of an accelerated development process over the last
eight months.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240227401198/en/
(Photo: Business Wire)
The KnowU incorporates the sensor that the Company plans to
submit to the FDA for clearance. This proprietary sensor has been
tested and proven stable and accurate in the lab setting. It was
included in the Company’s prototype to validate stability outside
of the lab, and is now miniaturized and wearable.
The KnowU can be worn with an adhesive, allowing the user to
clip the sensor on and off, or on the wrist or forearm with a
strap. The device, which is significantly smaller and lighter than
the prototype, includes on-board computing power and built-in
machine learning capabilities. The KnowU is designed to optimize
the customer experience – expected to last for years, eliminate
costly disposables, have a rechargeable battery, and connect with
an easy-to-use companion mobile app. Click here to watch a video
for more insight into specific KnowU features.
The KnowU brings Know Labs closer to delivering the world’s
first non-invasive blood glucose monitor to the global marketplace.
As the Company prepares for FDA clinical trials, the KnowU device
will support accelerated data collection, including determining the
technology’s performance throughout continuous wear, on different
locations on the body, and within more expansive glycemic ranges
and diverse populations.
“The prevalence of diabetes is growing globally at an alarming
rate. Millions of people face significant barriers in accessing the
technology and treatment they need to effectively manage their
diabetes,” said Ron Erickson, CEO and Chairman at Know Labs. “Know
Labs is committed to delivering an accessible, affordable, and
accurate solution that improves the current standard of care and
enhances the quality of life for those living with diabetes. The
KnowU brings us closer to a future where equitable care in diabetes
management will become a reality.”
The KnowU is built upon the solid scientific foundation
underlying Know Labs’ technology. Its proprietary radiofrequency
(RF) sensor measures glucose levels using dielectric spectroscopy
by rapidly scanning a large range of RF frequencies. It records
voltage values detected at each frequency to quantify, with
trade-secret machine learning algorithms, real-time continuous
blood glucose levels. The KnowU exploits the dielectric properties
of glucose, a polar molecule in the body, including its ability to
store electrical energy in an electrical field (known as
permittivity) as measured through a voltage reading received after
broadcasting each frequency. As the leading worldwide IP holder in
non-invasive blood glucose monitoring with more than 270 patents
issued, pending and in process, Know Labs has created a defensible
moat surrounding its technology. For more information, visit
https://www.knowlabs.co/technology.
During 2024, Know Labs will deploy the KnowU in large-scale,
external clinical trials while making refinements to the device and
its algorithms. To learn more about the development process for the
KnowU, visit https://www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
platform technology uses spectroscopy to direct electromagnetic
energy through a substance or material to capture a unique
molecular signature. The technology can be integrated into a
variety of wearable, mobile or bench-top form factors. This
patented and patent-pending technology makes it possible to
effectively identify and monitor analytes that could only
previously be performed by invasive and/or expensive and
time-consuming lab-based tests. The first application of the
technology will be in a product marketed as a non-invasive glucose
monitor. The device will provide the user with accessible and
affordable real-time information on blood glucose levels. This
product will require U.S. Food and Drug Administration clearance
prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2023, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227401198/en/
For Know Labs Media Inquiries Contact: Matter Health Abby
Mayo Knowlabs@matternow.com Ph. (617) 272-0592
Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co
Ph. (206) 629-6414
Grafico Azioni Know Labs (AMEX:KNW)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Know Labs (AMEX:KNW)
Storico
Da Nov 2023 a Nov 2024
